|
1
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Suker M, Beumer BR, Sadot E, Marthey L,
Faris JE, Mellon EA, El-Rayes BF, Wang-Gillam A, Lacy J, Hosein PJ,
et al: FOLFIRINOX for locally advanced pancreatic cancer: A
systematic review and patient-level meta-analysis. Lancet Oncol.
17:801–810. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Evans DB, Abbruzzese JL and Willett CG:
Cancer of the pancreasCancer: Principles and Practice of Oncology.
6th. DeVita VT Jr, Hellman S and Rosenberg SA: Lippincott Williams
and Wilkins; Philadelphia: pp. 1126–1161. 2001
|
|
4
|
Von Hoff DD, Ramanathan RK, Borad MJ,
Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias
JL, et al: Gemcitabine plus nab-paclitaxel is an active regimen in
patients with advanced pancreatic cancer: A phase I/II trial. J
Clin Oncol. 29:4548–4554. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al Groupe Tumeurs Digestives of Unicancer, ;
PRODIGE Intergroup, : FOLFIRINOX versus gemcitabine for metastatic
pancreatic cancer. N Engl J Med. 364:1817–1825. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gelmon K: The taxoids: Paclitaxel and
docetaxel. Lancet. 344:1267–1272. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Donaldson KL, Goolsby GL, Kiener PA and
Wahl AF: Activation of p34cdc2 coincident with taxol-induced
apoptosis. Cell Growth Differ. 5:1041–1050. 1994.PubMed/NCBI
|
|
8
|
Schiff PB, Fant J and Horwitz SB:
Promotion of microtubule assembly in vitro by taxol. Nature.
277:665–667. 1979. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang D, Sun L, Xian W, Liu F, Ling G,
Xiao L, Liu Y, Peng Y, Haruna Y and Kanwar YS: Low-dose paclitaxel
ameliorates renal fibrosis in rat UUO model by inhibition of
TGF-beta/Smad activity. Lab Invest. 90:436–447. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou J, Zhong DW, Wang QW, Miao XY and Xu
XD: Paclitaxel ameliorates fibrosis in hepatic stellate cells via
inhibition of TGF-β/Smad activity. World J Gastroenterol.
16:3330–3334. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hirose A, Tajima H, Ohta T, Tsukada T,
Okamoto K, Nakanuma S, Sakai S, Kinoshita J, Makino I, Furukawa H,
et al: Low-dose paclitaxel inhibits the induction of
epidermal-mesenchymal transition in the human cholangiocarcinoma
CCKS-1 cell line. Oncol Lett. 6:915–920. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tajima H, Ohta T, Shinbashi H, Hirose A,
Tsukada T, Okamoto K, Nakanuma S, Sakai S, Furukawa H, Makino I, et
al: Successful treatment of unresectable gallbladder cancer with
low-dose paclitaxel as palliative chemotherapy after failure of
gemcitabine and oral S-1: A case report. Oncol Lett. 4:1281–1284.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tajima H, Ohta T, Shinbashi H, Hirose A,
Okazaki M, Yamaguchi T, Ohbatake Y, Okamoto K, Nakanuma S, Sakai S,
et al: Phase I study of weekly palliative chemotherapy with
low-dose third-line paclitaxel for biliary tract cancer. Mol Clin
Oncol. 6:753–757. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ueno H, Ioka T, Ikeda M, Ohkawa S,
Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, et
al: Randomized phase III study of gemcitabine plus S-1, S-1 alone,
or gemcitabine alone in patients with locally advanced and
metastatic pancreatic cancer in Japan and Taiwan: GEST study. J
Clin Oncol. 31:1640–1648. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Uesaka K, Boku N, Fukutomi A, Okamura Y,
Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto
H, et al JASPAC 01 Study Group, : Adjuvant chemotherapy of S-1
versus gemcitabine for resected pancreatic cancer: A phase 3,
open-label, randomised, non-inferiority trial (JASPAC 01). Lancet.
388:248–257. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Okada S, Sakata Y, Matsuno S, Kurihara M,
Sasaki Y, Ohashi Y and Taguchi T; Cooperative Group of Docetaxel
for Pancreatic Cancer in Japan, : Phase II study of docetaxel in
patients with metastatic pancreatic cancer: A Japanese cooperative
study. Br J Cancer. 80:438–443. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ryan DP, Kulke MH, Fuchs CS, Grossbard ML,
Grossman SR, Morgan JA, Earle CC, Shivdasani R, Kim H, Mayer RJ, et
al: A Phase II study of gemcitabine and docetaxel in patients with
metastatic pancreatic carcinoma. Cancer. 94:97–103. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jones DV Jr, Lozano R, Hoque A, Markowitz
A, Patt YZ and Phase II: Phase II study of paclitaxel therapy for
unresectable biliary tree carcinomas. J Clin Oncol. 14:2306–2310.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Maeda S, Motoi F, Onogawa T, Morikawa T,
Shigeru O, Sakata N, Takadate T, Naitoh T, Rikiyama T, Katayose Y,
et al: Paclitaxel as second-line chemotherapy in patients with
gemcitabine-refractory pancreatic cancer: A retrospective study.
Int J Clin Oncol. 16:539–545. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Baek I, Bai CZ, Hwang J, Nam HY, Park JS
and Kim DJ: Paclitaxel coating of the luminal surface of
hemodialysis grafts with effective suppression of neointimal
hyperplasia. J Vasc Surg. 55:806–814.e1. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Choi HS, Savard CE, Choi JW, Kuver R and
Lee SP: Paclitaxel interrupts TGF-beta1 signaling between
gallbladder epithelial cells and myofibroblasts. J Surg Res.
141:183–191. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Taghian AG, Abi-Raad R, Assaad SI, Casty
A, Ancukiewicz M, Yeh E, Molokhia P, Attia K, Sullivan T, Kuter I,
et al: Paclitaxel decreases the interstitial fluid pressure and
improves oxygenation in breast cancers in patients treated with
neoadjuvant chemotherapy: Clinical implications. J Clin Oncol.
23:1951–1961. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Von Hoff DD, Ramanathan RK, Borad MJ,
Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias
JL, et al: Gemcitabine plus nab-paclitaxel is an active regimen in
patients with advanced pancreatic cancer: A phase I/II trial. J
Clin Oncol. 29:4548–4554. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Alvarez R, Musteanu M, Garcia-Garcia E,
Lopez-Casas PP, Megias D, Guerra C, Muñoz M, Quijano Y, Cubillo A,
Rodriguez-Pascual J, et al: Stromal disrupting effects of
nab-paclitaxel in pancreatic cancer. Br J Cancer. 109:926–933.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shukuya T, Yasui H, Boku N, Onozawa Y,
Fukutomi A, Yamazaki K, Taku K, Kojima T and Machida N: Weekly
Paclitaxel after failure of gemcitabine in pancreatic cancer
patients with malignant ascites: A retrospective study. Jpn J Clin
Oncol. 40:1135–1138. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cereda S and Reni M: Weekly docetaxel as
salvage therapy in patients with gemcitabine-refractory metastatic
pancreatic cancer. J Chemother. 20:509–512. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tajima H, Ohta T, Shoji Y, Watanabe T,
Makino I, Hayashi H, Nakagawara H, Onishi I, Takamura H, Ninomiya
I, et al: Expression of epithelial-mesenchymal transition markers
in locally recurrent hepatocellular carcinoma after radio frequency
ablation. Exp Ther Med. 1:347–350. 2010. View Article : Google Scholar
|
|
29
|
Schrama JG, de Boer MM, Baars JW,
Schornagel JH and Rodenhuis S: Palliative chemotherapy after
failure of high-dose chemotherapy in breast cancer-toxicity and
efficacy. Anticancer Res. 23(3C): 1–2800. 2003.PubMed/NCBI
|
